Literature DB >> 11158250

Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy.

E A Thomas1, P E Danielson, P A Nelson, T M Pribyl, B S Hilbush, K W Hasel, J G Sutcliffe.   

Abstract

In contrast to typical neuroleptic drugs, which have high affinities for dopamine D2 receptors, clozapine binds to multiple neurotransmitter receptors. The mechanisms responsible for its superior clinical efficacy over typical neuroleptics remain unknown. Using an automated genomics approach, total gene expression analysis (TOGA), we found an approximately threefold increase in the accumulation of the mRNA encoding apolipoprotein D (apoD) in mouse striatum in response to chronic treatment with clozapine. While in control animals, apoD is expressed predominantly in astrocytes, in situ hybridization and immunohistochemical studies indicated a substantial increase in apoD expression in neurons of the striatum, globus pallidus and thalamus after 2 weeks of clozapine treatment. Clozapine-induced increases in apoD expression were also observed in some white matter regions. These results suggest that apoD is a mediator in the mechanisms of clozapine and thus that deficiencies in aspects of lipid metabolism may be responsible for psychoses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158250     DOI: 10.1046/j.1471-4159.2001.00027.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  14 in total

Review 1.  Open-system approaches to gene expression in the CNS.

Authors:  J G Sutcliffe
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

2.  Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders.

Authors:  E A Thomas; B Dean; G Pavey; J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

3.  Expression profiling to understand actions of NMDA/glutamate receptor antagonists in rat brain.

Authors:  Petri Törönen; Marcus Storvik; Anni-Maija Lindén; Outi Kontkane; Markéta Marvanová; Merja Lakso; Eero Castrén; Garry Wong
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 4.  Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders.

Authors:  Elizabeth A Thomas
Journal:  Mol Neurobiol       Date:  2006-10       Impact factor: 5.590

5.  Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease.

Authors:  Paula A Desplats; James R Lambert; Elizabeth A Thomas
Journal:  Neurobiol Dis       Date:  2008-05-22       Impact factor: 5.996

6.  Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia.

Authors:  Christoph D Schmid; Lauren N Sautkulis; Patria E Danielson; Judith Cooper; Karl W Hasel; Brian S Hilbush; J Gregor Sutcliffe; Monica J Carson
Journal:  J Neurochem       Date:  2002-12       Impact factor: 5.372

7.  Age-related changes of apolipoprotein D expression in female rat central nervous system with chronic estradiol treatment.

Authors:  Cristina Pérez; Ana Navarro; Eva Martínez; Cristina Ordóñez; Eva Del Valle; Jorge Tolivia
Journal:  Age (Dordr)       Date:  2011-07-15

Review 8.  The neurobiology of apolipoproteins in psychiatric disorders.

Authors:  J Gregor Sutcliffe; Elizabeth A Thomas
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.590

9.  Apolipoproteins in the brain: implications for neurological and psychiatric disorders.

Authors:  David A Elliott; Cyndi Shannon Weickert; Brett Garner
Journal:  Clin Lipidol       Date:  2010-08-01

10.  Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems.

Authors:  Haiqun Jia; Ryan J Kast; Joan S Steffan; Elizabeth A Thomas
Journal:  Hum Mol Genet       Date:  2012-09-10       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.